The Predictive Value of Semi-quantitative Index of(99m)Tc-3PRGD(2) SPECT/CTfor Patients with HER2 Positive Breast Cancer

1367 Objectives: To investigated the predictive value of semi-quantitative index of 99mTc-3PRGD2 SPECT/CT for patients with HER2 positive breast cancer. Methods: There were 45 patients (53.0±9.5 years old) with suspected breast malignant nodules or masses from October 2016 to June 2017. The patients were examined with SPECT/CT in position after injecting 99mTc-3PRGD2 2 hours. All cases had pathological results.ER,PR, HER2, and Ki67 were obtained by immunohistochemistry and fluorescence in situ hybridization (FISH). The Mann-Whitney U test was used to compare SPECT/CT parameters according to independent breast cancer subgroup.Results 35 patients with invasive ductal carcinoma were confirmed by pathology. There were 7 patients in stage I, 11 patients in stage IIA and 17 patients in stage IIB according to the 2017 NCCN breast cancer guide. The cases of four breast cancer subtypes (luminalA subtype, luminalB subtype, HER2 subtype, triple negative subtype) were 6, 9, 9 and 11, respectively. The T/NT values were significantly higher in the HER2 subtype than in the triple negative subtype (5.03±1.77 vs 3.00±0.99,Z=-2.40,P=0.02). And the T/NT values were significantly higher in the patients in stage IIB than in stage I and IIA (4.54±1.46 vs 3.32±1.72,Z=-2.23,P=0.03). Besides, the T/NT values were significantly higher in the HER2-positive group than in the HER2-negative group (5.03±1.77 vs 3.53±1.52,Z=-2.10,P=0.04). The T/NT values were significantly higher in the lymph nodes metastasis positive group than in the negative group (4.79±1.38 vs 2.88±1.45, Z=-3.53,P=0.00). There was no statistical difference between ER-positive group and ER-negative group, PR positive group, and PR negative group, Ki67 positive group and Ki67 negative group (4.02±1.86vs3.85±1.63,4.12±1.66vs3.45±1.76,4.11±1.84vs3.48±1.28, P= 0.65, 0.28, 0.29, respectively). Conclusions 99mTc-3PRGD2 SPECT/CT semi-quantitative index has the predictive value with the expression of HER2 of patients with breast cancer to some extent. It deserves further study to identify this role for breast cancer. [Keywords] RGD;SPECT/CT;HER2;Breast cancer Table 1.The clinical and pathology of patients Table 2.The values of T/NT of 99mTc-3PRGD2 SPECT/CT